QUINAPRIL- quinapril hydrochloride tablet, film coated

国家: 美国

语言: 英文

来源: NLM (National Library of Medicine)

有效成分:

QUINAPRIL HYDROCHLORIDE (UNII: 33067B3N2M) (QUINAPRILAT - UNII:34SSX5LDE5)

可用日期:

NuCare Pharmaceuticals, Inc.

INN（国际名称）:

QUINAPRIL HYDROCHLORIDE

组成:

QUINAPRIL 20 mg

给药途径:

ORAL

处方类型:

PRESCRIPTION DRUG

疗效迹象:

Hypertension Quinapril tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention,

產品總結:

Quinapril tablets, USP are supplied as follows: Quinapril Tablets USP, 20 mg are brown colored, circular shaped film-coated tablets, debossed with D on one side and 16 on the other side. Bottles of 30 NDC 68071-3258-3 Bottles of 28 NDC 68071-3258-8 Dispense in well-closed containers as defined in the USP. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light. Manufactured for: Aurobindo Pharma USA, Inc. 2400 Route 130 North Dayton, NJ 08810 Manufactured by: Aurobindo Pharma Limited Unit-VII (SEZ) Mahaboob Nagar (Dt)-509302 India Revised: 03/2017

授权状态:

Abbreviated New Drug Application

产品特点

QUINAPRIL- QUINAPRIL HYDROCHLORIDE TABLET, FILM COATED
NUCARE PHARMACEUTICALS, INC.
----------
QUINAPRIL TABLETS, USP
RX ONLY
WARNING: FETAL TOXICITY
WHEN PREGNANCY IS DETECTED, DISCONTINUE QUINAPRIL HYDROCHLORIDE AS
SOON AS POSSIBLE.
DRUGS THAT ACT DIRECTLY ON THE RENIN-ANGIOTENSIN SYSTEM CAN CAUSE
INJURY AND DEATH TO THE
DEVELOPING FETUS (SEE WARNINGS: FETAL TOXICITY).
DESCRIPTION
Quinapril hydrochloride is the hydrochloride salt of quinapril, the
ethyl ester of a non-sulfhydryl,
angiotensin-converting enzyme (ACE) inhibitor, quinaprilat.
Quinapril hydrochloride is chemically described as [3S-[2[R*(R*)],
3R*]]-2-[2-[[1-(ethoxycarbonyl)-3-
phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic
acid,
monohydrochloride. Its molecular formula is C
H
N
O
•HCl and its structural formula is:
Quinapril hydrochloride USP is a white to off-white powder, with a
pink cast at times that is freely
soluble in aqueous solvents.
Quinapril tablets, USP contain 5 mg, 10 mg, 20 mg, or 40 mg of
quinapril for oral administration. Each
tablet also contains colloidal silicon dioxide, crospovidone, hydroxy
propyl cellulose, hypromellose,
iron oxide red, lactose monohydrate, magnesium carbonate, magnesium
stearate, polyethylene glycol,
povidone, and titanium dioxide.
CLINICAL PHARMACOLOGY
MECHANISM OF ACTION
Quinapril is deesterified to the principal metabolite, quinaprilat,
which is an inhibitor of ACE activity in
human subjects and animals. ACE is a peptidyl dipeptidase that
catalyzes the conversion of angiotensin I
to the vasoconstrictor, angiotensin II. The effect of quinapril in
hypertension and in congestive heart
25
30
2
5
failure (CHF) appears to result primarily from the inhibition of
circulating and tissue ACE activity,
thereby reducing angiotensin II formation. Quinapril inhibits the
elevation in blood pressure caused by
intravenously administered angiotensin I, but has no effect on the
pressor response to angiotensin II,
norepinephrine or epinephrine. Angiotensin II also stimulates the
secretion of al